Cidara Therapeutics Stock Analysis
CDTX Stock | USD 23.08 0.61 2.71% |
Cidara Therapeutics is undervalued with Real Value of 25.34 and Target Price of 31.5. The main objective of Cidara Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cidara Therapeutics is worth, separate from its market price. There are two main types of Cidara Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cidara Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cidara Therapeutics is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Cidara Stock trading window is adjusted to America/New York timezone.
Cidara |
Cidara Stock Analysis Notes
About 69.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.51. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cidara Therapeutics recorded a loss per share of 26.82. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 24th of April 2024. Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Cidara Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 89 people. For more info on Cidara Therapeutics please contact Jeffrey Stein at 858 752 6170 or go to https://www.cidara.com.Cidara Therapeutics Investment Alerts
Cidara Therapeutics had very high historical volatility over the last 90 days | |
The company reported the previous year's revenue of 1.27 M. Net Loss for the year was (169.83 M) with loss before overhead, payroll, taxes, and interest of (70.6 M). | |
Cidara Therapeutics currently holds about 53.08 M in cash with (176.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
Cidara Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 69.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Wall Street Analysts Predict a 64.5 percent Upside in Cidara Therapeutics Heres What You Should Know |
Cidara Therapeutics Upcoming and Recent Events
Earnings reports are used by Cidara Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
28th of March 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Cidara Largest EPS Surprises
Earnings surprises can significantly impact Cidara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2023-03-23 | 2022-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2024-03-27 | 2023-12-31 | -0.1 | -0.04 | 0.06 | 60 | ||
2023-11-02 | 2023-09-30 | -0.16 | -0.09 | 0.07 | 43 |
Cidara Therapeutics Environmental, Social, and Governance (ESG) Scores
Cidara Therapeutics' ESG score is a quantitative measure that evaluates Cidara Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cidara Therapeutics' operations that may have significant financial implications and affect Cidara Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Cidara Stock Institutional Investors
Shares | Blackrock Inc | 2024-12-31 | 55.5 K | Longwood Capital Partners Llc | 2024-12-31 | 54.5 K | Ikarian Capital, Llc | 2024-12-31 | 53.9 K | Geode Capital Management, Llc | 2024-12-31 | 53.1 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 49.6 K | Stempoint Capital Lp | 2024-12-31 | 47.6 K | Ubs Group Ag | 2024-12-31 | 46.9 K | Susquehanna International Group, Llp | 2024-12-31 | 42.6 K | Millennium Management Llc | 2024-12-31 | 36 K | Bvf Inc | 2024-12-31 | 1.1 M | Ra Capital Management, Llc | 2024-12-31 | 1.1 M |
Cidara Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 246.13 M.Cidara Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.79) | (0.83) | |
Return On Capital Employed | (1.07) | (1.01) | |
Return On Assets | (0.79) | (0.83) | |
Return On Equity | (1.04) | (0.99) |
Management Efficiency
Cidara Therapeutics has return on total asset (ROA) of (0.4046) % which means that it has lost $0.4046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1959) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2025. Return On Capital Employed is likely to rise to -1.01 in 2025. At this time, Cidara Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 20.2 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 2.8 M in 2025.Last Reported | Projected for Next Year | ||
Book Value Per Share | 25.72 | 24.43 | |
Tangible Book Value Per Share | 25.72 | 24.43 | |
Enterprise Value Over EBITDA | 0.09 | 0.09 | |
Price Book Value Ratio | 1.05 | 1.10 | |
Enterprise Value Multiple | 0.09 | 0.09 | |
Price Fair Value | 1.05 | 1.10 | |
Enterprise Value | -15.6 M | -14.8 M |
Understanding the operational decisions made by Cidara Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 24th of March, Cidara Therapeutics shows the risk adjusted performance of 0.0231, and Mean Deviation of 3.36. Cidara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cidara Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cidara Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cidara Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cidara Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cidara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cidara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cidara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cidara Therapeutics Outstanding Bonds
Cidara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cidara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cidara bonds can be classified according to their maturity, which is the date when Cidara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
US171779AL52 Corp BondUS171779AL52 | View | |
CIMAREX ENERGY 39 Corp BondUS171798AD34 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Cidara Therapeutics Predictive Daily Indicators
Cidara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cidara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cidara Therapeutics Corporate Filings
F4 | 13th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10K | 6th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
F3 | 26th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
14th of February 2025 Other Reports | ViewVerify | |
8K | 7th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
2nd of January 2025 Other Reports | ViewVerify | |
S1 | 23rd of December 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Cidara Therapeutics Forecast Models
Cidara Therapeutics' time-series forecasting models are one of many Cidara Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cidara Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cidara Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cidara Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cidara shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cidara Therapeutics. By using and applying Cidara Stock analysis, traders can create a robust methodology for identifying Cidara entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (133.56) | (126.88) | |
Operating Profit Margin | (138.12) | (131.21) | |
Net Loss | (133.20) | (126.54) | |
Gross Profit Margin | (65.57) | (62.30) |
Current Cidara Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cidara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cidara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
31.5 | Strong Buy | 5 | Odds |
Most Cidara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cidara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cidara Therapeutics, talking to its executives and customers, or listening to Cidara conference calls.
Cidara Stock Analysis Indicators
Cidara Therapeutics stock analysis indicators help investors evaluate how Cidara Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cidara Therapeutics shares will generate the highest return on investment. By understating and applying Cidara Therapeutics stock analysis, traders can identify Cidara Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 35.8 M | |
Common Stock Shares Outstanding | 6.3 M | |
Total Stockholder Equity | 163.3 M | |
Property Plant And Equipment Net | 4 M | |
Cash And Short Term Investments | 189.8 M | |
Cash | 189.8 M | |
Accounts Payable | 3.6 M | |
Net Debt | -186.2 M | |
50 Day M A | 21.8606 | |
Total Current Liabilities | 49.6 M | |
Other Operating Expenses | 177.4 M | |
Non Current Assets Total | 4.1 M | |
Forward Price Earnings | 5.7504 | |
Non Currrent Assets Other | 96 K | |
Stock Based Compensation | 3.9 M |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.